Indxx Licenses India Big 5 Conglomerates Index to Korea Investment Management for an ETF

New Delhi [India] September 19: Indxx, a provider of indexing solutions for exchange traded funds (ETFs), is pleased to announce the licensing of the Indxx India Big 5 Conglomerates Index to Korea Investment Management as the underlying benchmark for the ACE Indian Market Representative BIG5 Group Active ETF (Ticker: 487920), which began trading on the Korea Exchange (KRX) today.

The Indxx India Big 5 Conglomerates Index is designed to track the performance of India-listed companies that relate to or are subsidiaries of the 5 largest conglomerate businesses in India, as identified by Indxx.

Rahul Sen Sharma, President, and Co-CEO at Indxx said, “In January 2024, India achieved a significant milestone by becoming the world’s fourth-largest stock market, boasting a market capitalization exceeding $4 trillion. The country is also set to become the world’s third-largest economy by 2027. With established market positions and robust operational frameworks, India’s conglomerates are integral to its economic landscape, spearheading growth across diverse sectors such as manufacturing, finance, healthcare, and technology. Our Indxx India Big 5 Conglomerates Index offers exposure to these key players shaping India’s economic future and driving its growth. We are thrilled to collaborate with Korea Investment Management to bring this promising investment strategy to the Korean market.”

Vaibhav Agarwal, Chief Product Officer at Indxx added, “As major contributors to India’s GDP and employment landscape, conglomerates play a pivotal role in driving economic development. By leveraging in-depth research, the Indxx India Big 5 Conglomerates Index identifies the foremost conglomerates in India, offering a unique and targeted exposure to market leaders in the country.”

As of September 10, 2024, the index has 20 constituents. The index has been backtested to March 16, 2018, and has a live calculation date of April 30, 2024.

Founded in 2005, Indxx aims to deliver innovative and custom indexing and calculation solutions to the investment management community at large.

Indxx and products tracking its indices have been nominated for and received numerous awards, including ‘Index Provider of the Year’ at the With Intelligence Mutual Fund & ETF Awards 2022 & 2023, ‘Best Index Provider – Emerging Markets ETFs’ at the ETF Express US Awards in October 2020, and ‘Most Innovative ETF Index Provider’ for the Americas at the 14th Annual Global ETF Awards in July 2018.

Disclaimer: This article is for informational purposes only and does not constitute financial advice. Investing in stocks involves risk, and past performance is not indicative of future results. Readers should conduct their own research or consult with a qualified financial advisor before making any investment decisions.

aayush jain acquisition Business cashew processing cote d’ivoire esos 2026 pacific global fzco Pajson Agro pulkit jain Royal Mewa Share Swap

From Local to Global: Pajson Agro India to Acquire Pacific Global FZCO, Adding 60,000 MT Capacity at the World’s Largest Cashew Origin

All-stock 100% acquisition | ₹354.52 crore | Board also approves ESOS 2026 New Delhi [India], November 6: Pajson Agro India Limited (PAJSON | 544657 | INE14LM01012), a vertically integrated cashew processing company with farm-gate sourcing across key producing origins and a growing consumer brand, ‘Royal Mewa’, has announced that its Board of Directors, has approved […]

Read More
Business Fredun Pharmaceuticals EBITDA Growth Fredun Pharmaceuticals H1 FY27 Results Fredun Pharmaceuticals Net Profit Fredun Pharmaceuticals Revenue Growth Indian pharmaceutical industry

Fredun Pharmaceuticals On A Growth Overdrive: Net Profit Soars 94%, Ebitda Rockets 92% And Revenue Surges 87% In H1 Fy27

Mumbai (Maharashtra) [India], November 6: Fredun Pharmaceuticals Limited (BSE – FREDUN | 539730), one of India’s leading pharmaceutical formulation manufacturing companies, has announced its unaudited financial results for Q2 & H1 FY27. The Company offers a diversified portfolio spanning generics, cosmeceuticals, nutraceuticals, mobility solutions, and animal healthcare products. Key Financial Highlights Standalone key Financial Highlights […]

Read More
Business

Patil Automation Marks a Strong First Half of FY27; Consolidated Revenue Up 37% YoY, Net Profit Up 48%

Mumbai (Maharashtra) [India], November 6: Patil Automation Limited (NSE: PATILAUTOM | INE17GV01016), a leading provider of turnkey welding, assembly and robotics-integrated automation solutions, has released its Unaudited Standalone and Consolidated Financial Results for the half year ended September 30, 2026, reporting broad-based growth across the group. Performance Snapshot – H1 FY27 H1 FY27 Key Financial […]

Read More